Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
US Biomax is a leading biotechnology company specializing in the development and manufacture of high-quality tissue microarrays (TMA) and providing comprehensive biospecimen services. The company offers an extensive catalog of tissue sections, including human and animal tissues across various disease states such as oncology, inflammation, and metabolic disorders. Their products are designed to accelerate high-throughput molecular analysis, immunohistochemistry (IHC), and in situ hybridization (ISH) for researchers in academia and the pharmaceutical industry. Following its acquisition by BioIVT in 2022, US Biomax continues to support drug discovery and diagnostic development through its vast repository of clinically characterized tissue samples. The company is headquartered in Derwood, Maryland, and serves a global customer base.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on US Biomax.